The effects of cisplatin on the incorporation of fresh syngeneic and frozen allogeneic cortical bone grafts
โ Scribed by David J. Zart; Leslie Miya; David A. Wolff; John T. Makley; Dr. Sharon Stevenson
- Publisher
- Elsevier Science
- Year
- 1993
- Tongue
- English
- Weight
- 955 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0736-0266
No coin nor oath required. For personal study only.
โฆ Synopsis
Abstract
Allograft transplantation with concomitant chemotherapy has proven successful in the treatment of malignant bone tumors. However, these chemotherapeutic agents may delay tissue healing, resulting in clinical complications. To clarify the effects of cisplatin on the healing of bone grafts, we studied the incorporation of stably fixed massive diaphyseal femoral syngeneic and allogeneic grafts in rats treated with cisplatin. These data were compared with those of historical controls from animals that did not receive cisplatin. Rats that were to receive a fresh syngeneic graft or frozen allogeneic graft were given cisplatin every 4 weeks starting 9 weeks preoperatively and continuing until the time of death. The total bone area of the graft in animals that received cisplatin was smaller than that of the graft in untreated control rats that did not receive cisplatin. The area of the frozen allograft did not increase between 2 and 4 months. Revascularization was incomplete in cisplatinโtreated groups at 2 months, but by 4 months, vessel ingrowth in fresh syngeneic grafts approached control values. Frozen allografts remained poorly revascularized at 4 months. Hostโgraft union was poor at 2 months in cisplatinโtreated rats compared with controls. In cisplatinโtreated rats, the hostโgraft union of the frozen allograft remained inferior at 4 months while that of the syngeneic graft improved. Allogeneic cortical bone grafts are incorporated more slowly and incompletely than syngeneic grafts, and this handicap is exacerbated by the administration of cisplatin.
๐ SIMILAR VOLUMES
## Background: Non-melanoma skin carcinoma is more common in transplant recipients, probably because of immunosuppression. an increased risk of developing melanoma could be a late effect of transplantation. the number of naevi, which is a risk marker for melanoma, is increased in renal transplant r
## Abstract Bone morphogenetic proteins (BMPs) accelerate bone repair in experimental and clinical conditions. Impacted Morsellized Cancellous Bone grafts (MCB) are successfully used to reconstruct bone defects after failed hip implants. The main question in this study was if BMPโ7 (OPโ1) mixed wit